OOIR: Observatory of International Research

Papers

(The TQCC of New England Journal of Medicine is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)

Article	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	11994
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine	8280
Dexamethasone in Hospitalized Patients with Covid-19	7074
Empagliflozin in Heart Failure with a Preserved Ejection Fraction	2633
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant	2331
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	2191
Cytokine Storm	2159
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	2152
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	2053
Lecanemab in Early Alzheimer’s Disease	1993
Once-Weekly Semaglutide in Adults with Overweight or Obesity	1944
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant	1820
New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race	1811
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer	1777
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination	1777
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results	1746
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	1625
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months	1477
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma	1448
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19	1448
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes	1416
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022	1415
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer	1372
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	1357
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19	1355

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients	1352
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer	1282
Tirzepatide Once Weekly for the Treatment of Obesity	1279
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction	1253
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure	1247
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer	1234
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	1198
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers	1174
Severe Covid-19	1159
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia	1158
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination	1149
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	1142
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma	1119
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma	1105
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host	1100
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	1080
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	1064
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis	1057
Sotorasib for Lung Cancers with KRAS p.G12C Mutation	1047
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma	1038
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer	1028
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	1015
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia	1009
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis	1009
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities	996
Empagliflozin in Patients with Chronic Kidney Disease	990
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	973
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer	949
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	937
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis	899
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel	898
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients	889
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes	885
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab	844
Waning Immunity after the BNT162b2 Vaccine in Israel	841
Donanemab in Early Alzheimer’s Disease	836
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine	833
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants	833
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine	811
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer	805
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma	801
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	784
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer	783
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination	783
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes	783
Trial of Psilocybin versus Escitalopram for Depression	781
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers	770
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease	759
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients	739
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	736

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents	736
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19	733
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease	715
Pathophysiology of Inflammatory Bowel Diseases	711
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults	702
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile	700
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19	691
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons	683
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia	682
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar	675
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes	662
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women	651
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination	646
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine	645
Acquired Resistance to KRAS^G12C Inhibition in Cancer	639
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer	638
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma	634
Vaccine Breakthrough Infections with SARS-CoV-2 Variants	633
Racial Bias in Pulse Oximetry Measurement	625
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma	617
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest	614
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19	602
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer	599
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	594
Avacopan for the Treatment of ANCA-Associated Vasculitis	571
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease	570
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications	565
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa	550
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma	550
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	550
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma	546
Evidence of Artemisinin-Resistant Malaria in Africa	540
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	540
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines	537
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection	532
Osteoarthritis of the Knee	528
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19	521
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer	520
Diffuse Large B-Cell Lymphoma	520
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants	518
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	517
Neutralizing Activity of BNT162b2-Elicited Serum	516
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma	514
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer	514
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer	513
Teclistamab in Relapsed or Refractory Multiple Myeloma	500
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization	498
A Population-Based Study of Genes Previously Implicated in Breast Cancer	494
Endovascular Therapy for Acute Stroke with a Large Ischemic Region	490
A Bivalent Omicron-Containing Booster Vaccine against Covid-19	481
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19	478
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer	475
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel	474
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation	473
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients	472
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5	471
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer	468
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression	464
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma	464
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women	464
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer	457
Homologous and Heterologous Covid-19 Booster Vaccinations	457
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023	450
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age	447
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis	447
Race and Genetic Ancestry in Medicine — A Time for Reckoning with Racism	446
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer	444
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation	443
Microvascular Injury in the Brains of Patients with Covid-19	438
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase	438
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report	435
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity	432
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19	427
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes	426
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia	425
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections	422
Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018	418
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke	417
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure	412
Trial of Endovascular Thrombectomy for Large Ischemic Strokes	411

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer	410
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma	407
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine	407
Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct	402
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension	400
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS	398
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation	396
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	396
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines	393
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients	386
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons	383
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings	382
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis	378
Effect of Salt Substitution on Cardiovascular Events and Death	377
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH	376
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection	373
SARS-CoV-2 Variants in Patients with Immunosuppression	372
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants	372
Biologic Therapies for Severe Asthma	372
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease	370
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer	370
Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial	367
Atopic Dermatitis	367
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia	366
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19	359
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death	359
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease	357
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection	356
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion	355
Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue	355
Genetically Modified Porcine-to-Human Cardiac Xenotransplantation	353
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma	351
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk	350
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis	350
Current Causes of Death in Children and Adolescents in the United States	349
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer	349
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3	349
Pulmonary Arterial Hypertension	348
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer	348
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19	344
The Clinician and Dataset Shift in Artificial Intelligence	343
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination	343
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial	342
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion	340
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants	337
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron	334
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults	333
Transcatheter Repair for Patients with Tricuspid Regurgitation	332
Plasma Neutralization of the SARS-CoV-2 Omicron Variant	330
Long-Term Survival after Kidney Transplantation	329
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination	329
Physical Rehabilitation for Older Patients Hospitalized for Heart Failure	327
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition	326
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1	326
Covid-19 Vaccines — Immunity, Variants, Boosters	325
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant	325
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis	322
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar	322
Maintaining Safety with SARS-CoV-2 Vaccines	322
SARS-CoV-2 Variants and Vaccines	318
A Pandemic within a Pandemic — Intimate Partner Violence during Covid-19	316
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa	312
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis	311
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer	310
Sotatercept for the Treatment of Pulmonary Arterial Hypertension	310
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk	309
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico	307
Circadian Mechanisms in Medicine	307
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma	306
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion	305
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel	302
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2	301
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer	299
Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events	299
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome	297
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma	294
New Horizons in the Treatment of Osteosarcoma	292
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload	292
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission	292
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis	291
Long-Term Complications in Youth-Onset Type 2 Diabetes	290
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England	290
Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease	287
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection	287
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents	287
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction	287
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease	285
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants	284
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer	282
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes	280
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma	279
Extracorporeal Life Support in Infarct-Related Cardiogenic Shock	279
A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke	279
BNT162b2 Vaccine Booster and Mortality Due to Covid-19	276
Treatment for Mild Chronic Hypertension during Pregnancy	275